Julia R. Brinton

About Julia

Julia is an special counsel in Cooley's antitrust and competition practice and advises clients on antitrust issues, including mergers and acquisitions, compliance with the Hart-Scott-Rodino Act, and antitrust counseling. She has experience in matters before the US Department of Justice and Federal Trade Commission. Julia has worked with clients in several industries, including consumer goods, computer hardware and software, pharmaceuticals and medical devices, telecommunications, and aviation.

View full bio

Experience

EsoBiotec Announces up to $1 Billion Acquisition by AstraZeneca

March 17, 2025

Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.

Related contacts

Rama Padmanabhan

Partner, San Diego

Rowook Park

Partner, San Diego

Charity Williams

Partner, San Diego

Simon Amies

Partner, London

Russell Anderson

Partner, London

Megan Browdie

Partner, Washington, DC

Ross Eberly

Partner, Santa Monica

Christopher Kimball

Partner, Washington, DC

Charlie Lightfoot

Partner, London

Alessandra Murata

Partner, Palo Alto

Dr. Matthew Pavao

Partner, Boston

Guadalupe Sampedro

Partner, London

Stella Sarma

Partner, Brussels

Leo Spicer-Phelps

Partner, London

Nicola Squire

Partner, London

Chris Stack

Partner, London

Jeffrey J. Tolin

Partner, New York

David Wilson

Partner, London

Julia R. Brinton

Special Counsel, Washington, DC

Andrew Epstein

Special Counsel, Seattle

Jack Jones

Special Counsel, London

Dillon Martinson

Special Counsel, Washington, DC

Karen Tsai

Special Counsel, Washington, DC

Julie Wicklund

Special Counsel, Palo Alto

Natasha Leskovsek

Of Counsel, Washington, DC

Kafeel Azher

Associate, London

Sarah Buchik

Associate, New York

Dr. Jessica Cande

Associate, Boston

Mari Dugas

Associate, Washington, DC

Michael Fernando

Associate, London

Athina Gaki

Associate, Brussels

Elaine Huang

Associate, Palo Alto

Mark Jones

Associate, London

Eerik Kukebal

Associate, London

Chris Lynn

Associate, London

Morgan McCormack

Associate, London

Daniel Millard

Associate, London

Lindsey O'Crump

Associate, Washington, DC

Alexandra Paterson

Associate, London

Dr. Robert E. Powers

Associate, Boston

Zhijing Yu

Associate, Singapore

Kevin Gurley

Quantitative Analyst, New York

Related Practices & Industries

Mergers and Acquisitions

Life Sciences Corporate Partnering and Licensing

Life Sciences

Healthcare

Emerging Companies

Life Sciences and Healthcare Regulatory

Tax

Cyber/Data/Privacy

Antitrust and Competition

Compensation and Benefits

Commercial Litigation

Patent Counseling and Prosecution

Labor and Employment

CFIUS

Cooley Advises Special Committee of Checkpoint on Acquisition by Sun Pharma

March 9, 2025

Cooley advised the special committee of Checkpoint Therapeutics’ (Nasdaq: CKPT) board of directors in connection with Checkpoint’s definitive agreement to be acquired by Sun Pharmaceutical Industries (NSE: SUNPHARMA) for up to $416 million in cash and contingent value rights.

Related contacts

Bill Roegge

Partner, New York

Kevin Cooper

Partner, New York

Marc Recht

Partner, Boston

Wesley Dietrich

Associate, Washington, DC

Katie Benvenuti

Associate, New York

Michael Bergmann

Partner, Washington, DC

Eileen Marshall

Partner, Washington, DC

Alan W. Tamarelli

Partner, New York

Julia R. Brinton

Special Counsel, Washington, DC

Kristopher Kleiner

Special Counsel, Colorado

Rebecca Ross

Special Counsel, Washington, DC

Stella Sarma

Partner, Brussels

Natasha Leskovsek

Of Counsel, Washington, DC

Karun Ahuja

Special Counsel, Chicago

Elizabeth Caruso

Associate, New York

Matthew Choy

Associate, New York

Jameson Davis

Associate, Boston

Kyle Hess

Associate, New York

Allison Kutner

Associate, New York

Breanna Qin

Associate, Palo Alto

Arda Can Tekin

Associate, New York

Ryan Vann

Partner, Chicago

Related Practices & Industries

Mergers and Acquisitions

Life Sciences

Healthcare

Capital Markets

Cyber/Data/Privacy

Antitrust and Competition

Compensation and Benefits

Life Sciences Corporate Partnering and Licensing

Tax

Labor and Employment

Life Sciences and Healthcare Regulatory

CFIUS

Alani Nu’s $1.8 Billion Sale to Celsius

February 20, 2025

Cooley advised Katy Hearn and Haydn Schneider, co-founders of Alani Nu, in connection with Celsius Holdings’ (Nasdaq: CELH) definitive agreement to acquire the company for $1.8 billion in cash and stock.

Related contacts

Bill Roegge

Partner, New York

Stephanie Leigh

Paralegal Specialist, San Diego

Stephanie Gentile

Partner, New York

Jeremy Morrison

Partner, Washington, DC

Vicky Kandabarow

Associate, Washington, DC

Kyle Hess

Associate, New York

Wesley Dietrich

Associate, Washington, DC

Sharon Connaughton

Special Counsel, Washington, DC

Todd Gluth

Partner, San Diego

Sarah Lightdale

Partner, New York

Eileen Marshall

Partner, Washington, DC

Mark Windfeld-Hansen

Senior Counsel, Palo Alto

Julia R. Brinton

Special Counsel, Washington, DC

William Corcoran

Of Counsel, Boston

Related Practices & Industries

Mergers and Acquisitions

Antitrust and Competition

CooleyREG

Tax

Food and Beverage

Securities Litigation + Enforcement

Alumis Announces Merger With ACELYRIN

February 6, 2025

Cooley advised Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, on its definitive agreement with ACELYRIN to merge in an all-stock transaction.